Just-Evotec Biologics Expands its Partnership with Alpine Immune Sciences for the Commercial Process Development of ALPN-303 to Treat Systemic Lupus Erythematosus
Shots:
- Under the terms of the agreement, Just-Evotec will develop a commercial manufacturing process for Alpine’s ALPN-303 using its data-driven technology platform, J.DESIGN with the commercial development activities to be performed at its J.POD biomanufacturing facility
- The extension of the partnership was based on the 2020 collaboration under which Just-Evotech provided drug substance materials through J.DESIGN for the P-I & II studies of ALPN-303
- J.DESIGN is a highly automated biologics technology platform integrated with AI, ML intensified & continuous bioprocesses designed for flexible & efficient biologics development whereas ALPN-303 is a dual B cell cytokine (BAFF/APRIL) antagonist that treats inflammatory & autoimmune diseases incl. SLE
Ref: Businesswire | Image: Evotec
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
